Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
AssigneeThe Trustees of the University of Pennsylvania
InventorsHarvey Friedman, Drew Weissman, Sita Awasthi, Gary Cohen
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified m RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
Claims16
A composition comprising one or more nucleoside modified mRNAs encoding a) an HSV glycoprotein D (gD) or an immunogenic fragment thereof, b) an HSV glycoprotein C (gC) or an immunogenic fragment thereof, or c) an HSV glycoprotein E (gE) or an immunogenic fragment thereof, wherein the nucleic acid sequence of the nucleoside modified mRNA encoding said immunogenic fragment of HSV gD is as set forth in SEQ ID NO:
- 4;
- wherein the nucleic acid sequence of the nucleoside modified mRNA encoding said immunogenic fragment of HSV gC is as set forth in SEQ ID NO:
- 10;
- wherein the nucleic acid sequence of said nucleoside modified mRNA encoding said immunogenic fragment of HSV gE is as set forth in SEQ ID NO:
- 16;
- or a combination thereof and wherein said nucleoside modified mRNA comprises one or more pseudouridine residues.
Dependencies are inferred from the claim text.